| Identification | Back Directory | [Name]
ICI 162,846 | [CAS]
84545-30-2 | [Synonyms]
846
ICI 162
ICI 162,846
3-((imino((2,2,2-trifluoroethyl)amino)methyl)amino)-1h-pyrazole-1-pentanamid
3-[[Imino[(2,2,2-trifluoroethyl)amino]methyl]amino]-1H-pyrazole-1-pentanamide
N-[1-(4-CARBOXAMIDOBUTYL)-1H-PYRAZOL-3-YL]-N'-(2,2,2-TRIFLUOROETHYL)GUANIDINE
1H-Pyrazole-1-pentanamide, 3-[[imino[(2,2,2-trifluoroethyl)amino]methyl]amino]- | [Molecular Formula]
C11H17F3N6O | [MDL Number]
MFCD01310549 | [MOL File]
84545-30-2.mol | [Molecular Weight]
306.29 |
| Chemical Properties | Back Directory | [Boiling point ]
180°C (rough estimate) | [density ]
1.3025 (estimate) | [storage temp. ]
Store at RT | [solubility ]
Soluble in ethanol and to 100 mM in DMSO | [form ]
Powder |
| Hazard Information | Back Directory | [Uses]
ICI 162846 is a histamine H2-receptor antagonist. | [Definition]
ChEBI: 5-[3-[[amino(2,2,2-trifluoroethylimino)methyl]amino]-1-pyrazolyl]pentanamide is a fatty amide. | [Biological Activity]
A potent histamine H 2 receptor antagonist. | [in vivo]
ICI 162846 (10 mg/kg, p.o., twice daily for 5 days) reduces the incidence of CDU and inhibits acid production accompanied by an increase in the secretion of histamine in induced CDU models of CFLP mice[2]. | Animal Model: | CFLP mice were irradiated to the lower mediastinum to induce CDU[2]. | | Dosage: | 10 mg/kg, twice daily for 5 days | | Administration: | Oral gavage (p.o.) | | Result: | Reduced the incidence of CDU.
Inhibited gastric acid secretion about 50% or more in the basal and the stimulated periods.
Induced massive rises in basal (12-fold) and stimulated (9-fold) luminal histamine.
|
| [IC 50]
H2 Receptor | [storage]
Store at RT |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
http://m.approvedhomemanagement.com/ShowSupplierProductsList13285/0.htm |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
MOLEKULA Ltd.
|
| Tel: |
+44 (0) 1747 831066 |
| Website: |
www.molekula.co.uk |
|